
MAY - 3 2012





# SPIDENT Co., Ltd.

203 & 312, Korea Industrial Complex, 722, Gojan-Dong, Namdong-Gu, Incheon, Korea 405-821 Tel: +82(32)819-4570 Fax: +82(32)819-4572

# 510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92(c).

Date: <u>December. 22, 2011</u>

1. Company and Correspondent making the submission:

|         | Company  |
|---------|--|
| Name    | SPIDENT Co., Ltd.  |
| Address | 203 & 312, Korea Industrial Complex, 722,<br>Gojan-Dong, Namdong-Gu, Incheon, Korea<br>405-821 |
| Phone   | +82(32)819-4570  |
| Fax     | +82(32)819-4572  |
| Contact | J. M. Ahn/President  |

### 2. Device:

Proprietary Name – EsFlow Common Name – Tooth shade resin material Classification Name – material, tooth shade, resin

### 3. Predicate Device:

**ESTELITE FLOW QUICK, K051808** 

4. Classifications Names & Citations:

EBF, 872.3690

5. Description:

EsFlow is light-cured flowable composite resin which makes it ideal for small cavities in anterior and posterior teeth. It has the characteristics of good flowability, high compressive strength, and radiopaque. It has 17 shades: A1, A2, A3, A3.5, B2, B3, I, UO, LA1,LA2,LA3, LA3.5, LB2, LB3,LUO,White,Yellow.

EsFlow is similar to other commercially available products based on the intended use, the technology used, the claims, the material composition employed and performance characteristics. It is substantially equivalent in design, function and intended use to the predicate devices.



# SPIDENT Co., Ltd.

203 & 312, Korea Industrial Complex, 722, Gojan-Dong, Namdong-Gu, Incheon, Korea 405-821
Tel: +82(32)819-4570 Fax: +82(32)819-4572

### 6. Indication for use:

EsFlow is a low viscous, light cured hybrid composite dental tooth shade resin material. It is intended for use in various dental procedures, including direct anterior and posterior restorations (particularly for small/shallow/tunnel shaped cavities), as the first layer of direct restorations, blocking out cavity undercuts before fabricating indirect restorations, and repair of porcelain/composite materials.

### 7. Review:

The EsFlow has the similar device characteristics as the predicate device, the ESTELITE FLOW QUICK; intended use, material, chemical composition, design and use concept are similar.

The EsFlow has the similar mechanical properties as the predicate device; compressive strength, flexural strength, flow thickness, wear, polymerization shrinkage and thermal expansion coefficience.

The EsFlow has been subjected to extensive safety, performance, and product validations prior to release. Safety tests including biocompatibility have been performed to ensure the devices comply with the US regulations and ISO 4049.

Based on the comparison of intended use and technical features, the EsFlow is substantially equivalent to the predicate devices.

#### 8. Conclusions:

In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807, FDA's "Guidance for the Preparation of Premarket notifications for Dental Composite" and based on the information provided in this premarket notification SPIDENT Co., Ltd. concludes that the EsFlow is safe and effective and substantially equivalent to predicate devices as described herein.

9. SPIDENT Co., Ltd. will update and include in this summary any other information deemed reasonably necessary by the FDA.

**END** 

## DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Spident Company, Ltd C/O Mr. Marc M. Mouser Responsible Third Party Official Underwriters Laboratories, Inc. 2600 NW Lake Road Camas, Washington 98607

MAY - 3 2012

Re: K120768

Trade/Device Name: EsFlow

Regulation Number: 21 CFR 872.3690

Regulation Name: Tooth Shade Resin Material

Regulatory Class: II Product Code: EBF Dated: April 18, 2012 Received: April 26, 2012

Dear Mr. Mouser:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and

Radiological Health

510(k) Number: \_

(Division Sign-Off)

480768

000020

Division of Anesthesiology, General Hospital

Infection Control, Dental Devices